Development of a mechanism-based assay for tissue transglutaminase - Results of a high-throughput screen and discovery of inhibitors

Analytical Biochemistry

Volumn 338, Issue 2, 2005, Pages 237-244

  Case, April ^a   Ni, Jake ^a   Yeh, Li An ^a   Stein, Ross L ^a,b  

^a The Harvard Center for Neurodegeneration & Repair   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMATION; BIOMOLECULES; DIAGNOSIS; ENZYMES; SUBSTRATES; TISSUE;

AUTOMATED SCREENING; COMPOUND LIBRARIES; HIGH-THROUGHPUT SCREENS; INITIAL CONCENTRATION; INORGANIC PHOSPHATES; INTRACELLULAR PROTEINS; STEADY-STATE KINETICS; TISSUE TRANSGLUTAMINASE;

NEURODEGENERATIVE DISEASES;

CALCIUM ION; CASEIN; DANSYL CHLORIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SIMULATION; STEADY STATE; THERMODYNAMICS;

EID: 14644422536     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2004.09.047     Document Type: Article

References (27)

1. C. Soto Unfolding the role of protein misfolding in neurodegenerative diseases Nat. Rev. Neurosci. 4 2003 49 60
2. D.H. Perlmutter The cellular response to aggregated proteins associated with human disease J. Clin. Invest. 110 2002 1219 1220
3. M. Murphy Regina Peptide aggregation in neurodegenerative disease Ann. Rev. Biomed. Eng. 4 2002 155 174
4. J.P. Taylor, J. Hardy, and K.H. Fischbeck Toxic proteins in neurodegenerative disease Science 296 2002 1991 1995
5. E. Junn, R.D. Ronchetti, M.M. Quezado, S.Y. Kim, and M.M. Mouradian Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies Proc. Natl. Acad. Sci. 100 2003 2047 2052
6. T. De Cristofaro, A. Affaitati, L. Cariello, E.V. Avvedimento, and S. Varrone The length of polyglutamine tact, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates Biochem. Biophys. Res. Commun. 260 1999 150 158
7. V. Gentile, C. Sepe, M. Calvani, A.B.M. Melone, R. Cotrufo, A.J.L. Cooper, J.P. Blass, and G. Peluso Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains Arch. Biochem. Biophys. 352 1998 314 321
8. A.J.L. Copper, T.M. Jeitner, and J.P. Blass The role of transglutaminase in neurodegenerative diseases: overview Neurochem. Int. 40 2002 1 5
9. S.Y. Kim, T.M. Jeitner, and P.M. Steinert Transglutaminases in disease Neurochem. Int. 40 2002 85 103
10. M. Lesort, J. Tucholski, M.L. Miller, and G.V.W. Johnson Tissue transglutaminase: a possible role in neurodegenerative diseases Prog. Neurobiol. 61 2000 439 463
11. M. Sarvari, L. Fesus, and Z. Nemes transglutaminase-mediated crosslinking of neural proteins in Alzheimer's disease and other primary dementias Drug Dev. Res. 56 2002 458 472
12. S.M. Singer, B.M. Zainelli, M.A. Norlund, J.M. Lee, and N.A. Muma Transglutaminase bonds in neurofibrillary tangles and paired helical filament Tau early in Alzheimer's disease Neurochem. Int. 40 2002 17 30
13. M.L. Miller, and G.V.W. Johnson Transglutaminase cross-linking of the Tau protein J. Neurochem. 65 1995 1760 1770
14. G.V.W. Johnson, T.M. Cox, J.P. Lockhart, M.D. Zinnerman, M.L. Miller, and R.E. Powers Transglutaminase activity is increased in Alzheimer's disease brain Brain Res. 751 1997 323 329
15. P.G. Mastroberardino, C. Iannicola, R. Nardacci, F. Bernassola, V. Delaurenzi, G. Melino, S. Mereno, F. Pavone, S. Oliverio, L. Fesus, and M. Piacentini Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease Cell Death Differ. 9 2002 8873 8880
16. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedott, D. Mitchell, and L. Steinman Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 8 2002 143 149
17. A.J.L. Cooper, T.M. Jeitner, V. Gentile, and J.P. Blass Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats Neurochem. Int. 40 2002 53 67
18. ε-(γ-l-Glutamyl)-l-lysine is increased in cerebrospinal fluid of patients with Huntington's disease J. Neurochem. 79 2001 1109 1112
19. J.E. Folk Mechanism and basis for specificity of transglutaminase- catalyzed ε-(γ-glutamyl)lysine bond formation Adv. Enzymol. Relat. Areas Mol. Biol. 54 1983 1 56
20. J.E. Folk, and S. Chung Transglutaminases Methods Enzymol. 113 1985 358 375
21. A. Case, and R.L. Stein Kinetic analysis of the action of tissue transglutaminase on peptide and protein substrates Biochemistry 42 2003 9466 9481
22. C.M. Bergamini GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase FEBS Lett. 239 1988 255 258
23. h/transglutaminase II involves distinct residues in a unique GTP-binding pocket J. Biol. Chem. 275 2000 18259 18265
24. 2+ and GTP calcium binding on tissue transglutaminase tertiary structure J. Biochem. 275 2000 3915 3932
25. R. Casadio, E. Polverini, P. Mariani, F. Spinozzi, F. Carsughi, A. Fontana, P.P. De Laureto, G. Matteucci, and C.M. Bergamini The structural basis for the regulation of tissue transglutaminase by calcium ions Eur. J. Biochem. 262 1999 672 679
26. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
27. B.A. Citron, Z. Suo, K. Santacruz, P.J.A. Davies, F. Qin, and B.W. Festoff Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration Neurchem. Int. 40 2002 69 78